Category Archives: HIV Prevention Justice Alliance

  1. VOICE Lesson: It’s Unfair to be Non-Adherent

    This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

    adherence, Africa, hiv prevention, HIV Prevention Justice Alliance, HIV/AIDS policy, new prevention technologies, pre-exposure prophylaxis, PrEP, research, Tenofovir, Truvada, vaginal microbicide, VOICE
  2. PrEP: A Possible Approval Like No Other

    Via Poz, by Tim Horn The AIDS Healthcare Foundation began a paid advertisement campaign urging Gilead Sciences to refrain from seeking approval from the U.S. Food and Drug Administration for Truvada for use of the combination tablet as HIV prevention, in an approach known as pre-exposure prophylaxis, or PrEP. The ads were met by an outcry from the Read More >>

    clinical trials, HIV Prevention Justice Alliance, HIV/AIDS, Infections, iPrEx, MSM, NIAID, NIH, placebo, PrEP, Truvada
  3. Is Africa ready for PrEP?

    Via Incidence0.org, by Adebisi Ademola Alimi One of the biggest breakthrough in HIV clinical research, since the outbreak of the epidemic 30 years ago, is the recent success in a clinical trial of a new HIV prevention approach based on the daily use of the antiretroviral drug Truvada by HIV negative person to prevent HIV transmission (Called Read More >>

    antiretroviral therapy, ARV, clinical trials, heterosexual epidemic, HIV Prevention Justice Alliance, HIV/AIDS, Infections, iPrEx, PrEP, research, Truvada
  4. Q and A: Moving PrEP from Promising Trial Result to Practical, Public Health Prevention Intervention?

    by Julie Davids, AIDS Foundation of Chicago, HIV Prevention Justice Alliance and IRMA member As noted in these pages and press reports worldwide, the iPrex trial found that daily use of truvada protected gay men, other MSM and trangender women from HIV infection. Updated data presented at this week’s Conference on Retroviruses and Opportunistic Infections (CROI) showed Read More >>

    AVAC, CROI, Fenway community healthhiv prevention, HIV Prevention Justice Alliance, HIV/AIDS. pre-exposure prophylaxis, new prevention technologies, PrEP